The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics• Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease• The Oral Delivery Challenge: Why It Requires More Than the Right Route• Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development•
Capsugel Lonza — A Better Way to Deliver Microbiome-Based Therapies

Latest in the News

All News →
MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines
 CLINICAL & MANUFACTURING

MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines

Biocodex will invest €15 million in an anaerobic manufacturing facility in France to support MRM Health’s MH002 and other CORAL® programs toward potential commercial supply.

BY Microbiome Times · NOV 5, 2026 · 5 MIN READ
Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics
GASTROINTESTINAL

Beyond the small intestine: ileo colonic delivery as the next frontier for oral therapeutics

NOV 3, 2026
Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease
REGULATORY & POLICY

Scientists Call for a National Microbiome “Moonshot” to Tackle Chronic Disease

OCT 30, 2026
The Oral Delivery Challenge: Why It Requires More Than the Right Route
CLINICAL & MANUFACTURING

The Oral Delivery Challenge: Why It Requires More Than the Right Route

OCT 26, 2026
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets
BIOTICS AND SUPPLEMENTS

Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets

OCT 22, 2026
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development
CLINICAL & MANUFACTURING

Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development

OCT 16, 2026
Evonik EUDRACAP colon - GMP quality targeted drug delivery from the upper small intestine to the ileo-colonic region

Editor's Choice

All Editor's Choice →
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
 Editor's Choice

Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

Prokarium’s live bacterial immunotherapy ZH9 aims to redefine the non-muscle invasive bladder cancer treatment paradigm, building upon the precedence of BCG with a product designed for real-world urology practice.

BY Nick Glanville, Livija Deban and Dara Henry · SEP 28, 2026 · 9 MIN READ
A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
Editor's Choice

A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

SEP 1, 2026
Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
Editor's Choice

Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

AUG 10, 2026